EDAP TMS S.A. Dossier
Qualitative Analysis
Business overview
EDAP TMS SA (operating under the corporate name FocalTherics™ since June 1, 2026) is a global leader in robotic energy-based therapies. The company develops, manufactures, and markets minimally invasive medical devices utilizing proprietary focused ultrasound technology. Its flagship platform, Focal One® Robotic High-Intensity Focused Ultrasound (HIFU), combines advanced imaging, real-time treatment planning, and robotic precision to deliver personalized focal therapy for prostate tissue ablation. Effective January 1, 2026, the company transitioned from a foreign private issuer to a U.S. domestic filer status. To sharpen its strategic focus exclusively on high-growth robotic focal therapy, the company rebranded to FocalTherics and announced its intention to classify its legacy Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments as discontinued operations starting in Q2 2026.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
De-emphasizing and classifying legacy, lower-margin Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution businesses as discontinued operations starting in Q2 2026 to focus exclusively on the high-growth Focal One robotic focal therapy platform.
Expected impact: Aims to drive HIFU gross margins to approximately 60% and establish a clear pathway to operating breakeven and positive EBITDA by 2028.
Global commercial rollout of the Focal One i platform, the company's most advanced robotic HIFU system featuring enhanced clinical capabilities, five-axis robotic positioning, and seamless integration with next-generation imaging technologies.
Expected impact: Accelerates hospital adoption and increases procedure volumes by offering urologists superior imaging integration and clinical flexibility.
Expanding the therapeutic indications of the Focal One platform beyond prostate cancer into deep infiltrating endometriosis and Benign Prostatic Hyperplasia (BPH).
Expected impact: Unlocks a total addressable market of over 4 million annual procedures and more than $10 billion in potential revenue.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Explores the integration of Telix's PSMA PET diagnostic imaging scans (Gozellix and Illuccix) directly into the Focal One Robotic HIFU treatment workflow to optimize treatment planning, precise image-guided ablation, and post-treatment monitoring.
Terms: Non-promotional scientific, educational, and research engagement under a Letter of Intent signed in May 2026.
Secured a ’36 million multi-tranche credit facility to support the global commercial expansion of the Focal One Robotic HIFU platform and accelerate clinical development for new therapeutic indications.
Terms: EUR 36 million credit facility, with the first tranche of EUR 11 million expected to be drawn in Q4 2025.